Beardsworth® Selects OmniComm Systems® AE Reporting System
Safety Surveillance System to Complement OmniComm's TrialMaster EDC Solution
Sep. 23, 2010 (PR Newswire) --
FORT LAUDERDALE, Fla., Sept. 23 /PRNewswire/ -- OmniComm Systems, Inc. (OTC: OMCM), one of the fastest growing companies in the EDC marketplace, today announced that Beardsworth, a full service contract research organization (CRO) who specializes in difficult therapeutic areas, has selected OmniComm's AE Reporting System to enhance its safety reporting process. AE Reporting is an advanced adverse event reporting and information management system designed for the global collection, assessment, reporting, and analysis of clinical trial and post-marketing adverse events.
Michael O'Brien, Beardsworth's President & CEO states, "We are happy to incorporate OmniComm's AE Reporting System to broaden our ability in safety reporting, which is an essential element in the services to our clients." The robust functionality within AE Reporting will automate many of the complex activities associated with drug safety, including data entry, medical review, reporting and case distribution.
"We are extremely pleased that Beardsworth has selected AE Reporting to be part of its global safety surveillance practice," commented Stephen Johnson, President & COO of OmniComm Systems, Inc. "We are committed to providing leading solutions and services across the eClinical spectrum to aid our clients with their complex clinical research needs." Last year Beardsworth implemented OmniComm's TrialMaster EDC solution for capturing and processing clinical trial data. AE Reporting will be integrated with TrialMaster, to fully automate the safety handling process from the initial capture of the AE to the submission to the FDA and other regulatory authorities.
About Beardsworth
Beardsworth Consulting Group, Inc. (www.beardsworth.com) is a full-service CRO whose service offerings span all stages of drug development and clinical trial management. With a command of the complex trial, Beardsworth's niche expertise focuses on oncology/supportive care and vaccine/anti-infective therapeutics. In business since 1986, Beardsworth brings 20+ years of experience, expertise and commitment to provide solution-based business models for results on time and within budget. A woman-owned business, Beardsworth is proud to be WBENC-certified. Headquartered in Flemington, New Jersey, Beardsworth's network of medical monitors and strategic alliances provide a global reach that is local in connection. Beardsworth is the founding partner of OncologyOne – an alliance of "best in class" regional CROs providing full service business and research strategies for global oncology trials.
About OmniComm
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's pricing model is easily understood and allows companies ranging from small, to large, to maximize their clinical research investments. OmniComm Systems, Inc has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.
Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
CONTACT:
Mark Rice
OmniComm Systems, Inc.
858-259-2365
mjrice@omnicomm.com
SOURCE OmniComm Systems, Inc.
Mark Rice, OmniComm Systems, Inc., +1-858-259-2365, mjrice@omnicomm.com
Source: PR Newswire (September 23, 2010 - 9:00 AM EDT)
News by QuoteMedia
www.quotemedia.com
AI
